UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 1, 2012
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Nevada | | 0-22245 | | 87-0449967 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| 11975 El Camino Real, Suite 300, San Diego, California | | 92130 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(858) 222-8041
Not Applicable
| Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On June 1, 2012, Paul Maier was appointed to serve as a Class I director of Apricus Biosciences, Inc. Mr. Maier will serve as a member of the Board’s Audit Committee and Corporate Governance/Nominating Committee. In connection with his appointment as a director, Mr. Maier was awarded a stock option grant for 25,000 shares of the Company’s common stock under the Company’s 2006 Stock Incentive Plan.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | | Document |
| | | |
| 99.1 | | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| June 4, 2012 | Apricus Biosciences, Inc. | |
| | | | |
| | By: | /S/ RANDY BERHOLTZ | |
| | | Randy Berholtz | |
| | | Executive Vice President, General Counsel and Secretary | |
